* Cell Genesys Inc., of Foster City, Calif., received clearance to openfor enrollment a second Phase II trial of an AIDS gene therapy. Apatient's own T cells will be collected, genetically modified andreturned to the patient.
* Guilford Pharmaceuticals Inc., of Baltimore, said the FDA'sOncologic Drugs Advisory Committee will review the company'snew drug application for Gliadel June 14, 1996. Gliadel is abiodegradable wafer containing the cancer chemotherapeutic agent,carmustine. The wafers, which gradually release the drug to attackcancer cells, are implanted at the site of a brain tumor followingsurgery.
* Ligand Pharmaceuticals Inc., of San Diego, said it will have its nexttwo milestone payments from Pfizer Inc., of New York, paid inLigand stock. The $1.25 million in milestones will be paid through101,000 shares of the 1.35 million Ligand shares held by Pfizer.
* NPS Pharmaceuticals Inc., of Salt Lake City, said underwriters forits recent public offering exercised overallotment options on 450,000shares at $15 per share, increasing net proceeds to about $48.3million.
* Phyton Inc., of Ithaca, N.Y., entered a collaboration with PfizerInc., of New York, for application of the former's plant cell culturetechnology with the pharmaceutical firm's research into developmentof therapeutic compounds from natural products. Financial termswere not disclosed.
* The Liposome Co., of Princeton, N.J., said liposomal prostaglandinE1 (TLC C-53) was designated as an orphan drug for the treatment ofacute respiratory distress system. The drug currently is in a Phase IIItrial for that indication. The company also received approval tomarket Abelcet in Ireland as a first-line treatment for systemiccandidiasis and other fungal infections.
* Tital Pharmaceuticals Inc., of Menlo Park, Calif., said its TheracellInc. subsidiary signed a licensing agreement with the University ofSouth Florida College of Medicine to develop Sertoli cell technologyfor treatment of brain disorders. Theracell will obtain an exclusivelicense to the technology and invest at least $1.5 million over twoyears.
* Vertex Pharmaceuticals Inc., of Cambridge, Mass., signed anexclusive license and supply agreement with BioChem TherapeuticInc., of Laval, Quebec, for development and marketing in Canada ofVX-710, Vertex's lead multidrug reversal agent that's in Phase I/IIstudies. BioChem will pay an initial licensing fee and developmentand commercialization milestones.
* Vical Inc., of San Diego, expanded its 1994 agreement with PasteurMerieux Serums & Vaccins S.A., of Lyon, France, covering Vical's"naked" DNA technology for vaccines. The deal includes a researchcollaboration and an option for Pasteur Merieux to get exclusivelicenses to the technology for certain targets. Pasteur Merieux hasexercised four of five original license options and extended its optionfor the fifth.
(c) 1997 American Health Consultants. All rights reserved.